Is KPV on the 503A Bulks List? Current Status and Process

KPV is a synthetic tripeptide, not a brand-name drug, and it is sometimes confused with longer alpha-MSH fragments or with the acetylated dimer Ac-CKPV, which is a distinct compounded structure studied for candidacidal activity (Castro et al., 2005). None of these forms carries FDA approval for any human indication. This page addresses one narrow question: where does KPV stand in the 503A bulk drug substance process, and what would have to happen for a compounding pharmacy to legally use it under that pathway.

What the 503A bulks list actually controls

Section 503A of the FD&C Act lets state-licensed pharmacies and physicians compound drugs from bulk substances for individual patients, but only if the bulk substance meets specific criteria, one of which is appearing on FDA's 503A bulks list (or meeting an exception described in FDA's framework: Bulk Drug Substances Used in Compounding Under Section 503A). A substance not on that list, and not otherwise excepted, is not a lawful basis for 503A compounding, regardless of how it is marketed or sold. Being sold as a "research peptide" or through a compounding pharmacy's website does not change this.

This is a separate track from FDA drug approval. A substance can eventually land on the 503A bulks list without ever going through a New Drug Application, because 503A compounding is meant for patient-specific preparations, not mass manufacturing. But the bulks list still requires FDA to add the substance, and FDA has not added KPV.

What actually happened with KPV's regulatory status

Two separate events get conflated in marketing copy, and they mean different things.

First, KPV had been nominated to FDA's Category 2 list, a roster of bulk substances FDA identified as presenting significant safety risks that generally should not be compounded. The nominators withdrew that nomination, and per FDA's Category 2 page (content current 04/22/2026), KPV is no longer listed there: Certain Bulk Drug Substances FDA Has Identified as Presenting Significant Safety Risks. Withdrawal removes a negative determination. It is not an approval, a clearance, or a statement that KPV is safe to compound. FDA has not published a specific withdrawal date beyond noting the page's current content date, and this page will not manufacture one.

Second, on July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) met and voted 8 yes, 6 no, 1 abstain to recommend that KPV be added to the 503A bulks list (meeting page). PCAC is an advisory body. Its vote is a recommendation to FDA, not a rulemaking action, and the vote itself was close and not unanimous, which matters if the agency weighs committee dissent in its own review. As of September 2026, FDA has not added KPV to the 503A bulks list, and no interim enforcement discretion policy covers compounding it in the meantime.

Put together: KPV cleared one procedural hurdle (Category 2 removal) and received one favorable but non-binding advisory signal (the PCAC vote), and neither of those is the same as FDA action adding it to the 503A list. A reader who sees "KPV cleared by FDA committee" in advertising is seeing a compressed and inaccurate version of a two-step regulatory process that is still incomplete.

What has to happen next for KPV to become 503A-eligible

The remaining steps are FDA's, not the compounding industry's:

1. FDA reviews the PCAC recommendation alongside its own safety and efficacy analysis. The agency is not obligated to follow the committee's vote in either direction.
2. If FDA decides to move forward, it would need to publish the addition, typically through the same public process used for other 503A bulk substance additions, which includes public notice and comment.
3. Only after that addition is finalized would 503A-licensed pharmacies have express legal grounds to compound KPV preparations under this pathway, subject to standard 503A limits: patient-specific prescriptions, no copying of a commercially available drug, and compliance with USP compounding standards.

There is no published FDA timeline for step 1 or step 2 as of this writing, and speculating about a decision date would overstate what is currently known.

Does the withdrawal or the vote say anything about whether KPV works?

No, and this is where marketing tends to overreach. Category 2 withdrawal is a procedural safety-list decision, not an efficacy finding. The PCAC vote addressed the 503A bulks question, not a therapeutic claim. The actual evidence base for KPV's biological activity comes from a different literature: cell and tissue studies showing anti-inflammatory and antimicrobial effects of alpha-MSH-derived peptides (Journal of Leukocyte Biology, 2000; Annals of the NY Academy of Sciences, 2003), and rodent models of colitis and endotoxin-driven inflammation in which KPV reduced inflammatory markers (Gastroenterology, 2008; Inflammatory Bowel Diseases, 2008; Journal of Surgical Research, 2006). A 2008 review in Endocrine Reviews summarizes this preclinical anti-inflammatory profile across alpha-MSH-related tripeptides (Catania et al., 2008). Human clinical trial data for KPV itself remain limited; most of the mechanistic and efficacy signal is cell-culture or animal-model work, and that gap does not close just because the regulatory pathway advances. For a fuller look at the evidence in specific conditions, see the pillar page on KPV peptide research and mechanisms and the condition-specific review of KPV in inflammatory bowel disease.

Evidence boundary: what is established, what is not

Established: KPV's Category 2 nomination was withdrawn (current as of the FDA page's 04/22/2026 content date). PCAC voted 8-6-1 in July 2026 to recommend 503A listing. KPV is not currently on the 503A bulks list and is not FDA-approved for any indication.

Plausible but unproven: that FDA will eventually add KPV to the 503A list; the committee's recommendation is a signal, not a certainty, and the vote margin was narrow.

Not established: any human clinical efficacy or safety profile at a population level. The peptide literature is dominated by in vitro and animal-model findings on inflammation and antimicrobial activity, not controlled human trials.

What this means if you are considering a compounded KPV product now

A compounded KPV product sold today is not being dispensed under confirmed 503A bulk-substance authority, because that authority does not yet exist for this substance. That does not automatically make every such product illegal in every circumstance, since compounding law includes other exceptions and state-level variables, but it does mean the product is not resting on the specific legal foundation ("FDA-listed 503A bulk substance") that some sellers imply. If you are weighing a compounded KPV preparation against alternatives, the practical comparison points are covered in the review of KPV versus topical steroid approaches and the discussion of systemic KPV formulations. Anyone with an active flare of inflammatory bowel disease, uncontrolled skin infection, or another condition under specialist care should raise any peptide product with that clinician before use, since dosing and interaction data for KPV are not established well enough to self-manage around a prescribed treatment plan.

Decision checklist: is a KPV product's regulatory claim accurate?

Use this before trusting a vendor's regulatory language:

If a seller cannot point to which specific line in this table supports their claim, treat the claim as unverified.

For dosing questions once (or if) the regulatory picture changes, see KPV dosing considerations. For skin-specific applications, see KPV for eczema and psoriasis.